Literature DB >> 2521816

Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebo-controlled trial.

H Drexler1, U Banhardt, T Meinertz, H Wollschläger, M Lehmann, H Just.   

Abstract

To discover the underlying mechanisms involved in the beneficial long-term effects of angiotensin converting enzyme (ACE) inhibitors, we investigated the systemic and peripheral effects of short- and long-term ACE inhibition in patients with chronic heart failure. After assessing the short-term effects and dose titration with cilazapril, a new long-acting ACE inhibitor, 21 patients were randomized to receive either placebo or the ACE inhibitor. Seventeen patients completed the 3-month treatment. Central hemodynamic output, femoral blood flow (measured by thermodilution), oxygen saturation, and lactate and norepinephrine levels were determined simultaneously in the femoral vein and radial artery during treatment and after a 3-month rest and during symptom-limited bicycle exercise. Short-term ACE inhibition improved rest and exercise hemodynamic output, but it did not alter peak femoral blood flow, calculated leg oxygen consumption, or systemic oxygen uptake during exercise, despite significant reduction in femoral norepinephrine extraction and arterial angiotensin levels during exercise. In contrast, long-term ACE inhibition further improved exercise cardiac output and increased leg blood flow (from 2.3 to 2.9 l/min, p less than 0.05), leg oxygen consumption (from 277 to 403 ml/min, p less than 0.05), and systemic oxygen uptake (from 1,133 to 1,453 ml/min, p less than 0.05), whereas these variables remained unchanged with placebo treatment (p less than 0.02 between groups). Moreover, a moderate but significant increase in femoral oxygen extraction occurred after long-term therapy (ACE inhibitor: from 76% to 83%, p less than 0.05; placebo: from 75% to 74%, NS; p less than 0.01 between groups). We conclude that long-term ACE inhibition is clinically beneficial in that it improves blood flow to skeletal muscle during exercise over time. The long-term effects of ACE inhibition are, in part, probably related to peripheral (vascular) mechanisms, for example, by reversing the inability of peripheral vessels to dilate and by improving oxygen utilization.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521816     DOI: 10.1161/01.cir.79.3.491

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

Review 1.  Peripheral limitations of maximal aerobic capacity in patients with chronic heart failure.

Authors:  Stuart D Katz; Haoyi Zheng
Journal:  J Nucl Cardiol       Date:  2002 Mar-Apr       Impact factor: 5.952

2.  Management of heart failure.

Authors:  T H Le Jemtel
Journal:  Curr Cardiol Rep       Date:  2000-05       Impact factor: 2.931

3.  Percutaneous transvenous mitral commissurotomy immediately restores quick response of VO2 to mild exercise despite insignificant increases in peak VO2.

Authors:  H Takaki; K Sunagawa; M Sugimachi; J Tamai; Y Okano; T Kurita; N Aihara; W Shimizu; K Suyama; S Kamakura
Journal:  Heart Vessels       Date:  1995       Impact factor: 2.037

Review 4.  Vasodilators in heart failure. Conclusions from V-HeFT II and rationale for V-HeFT III.

Authors:  J N Cohn
Journal:  Drugs       Date:  1994       Impact factor: 9.546

5.  Endothelial control of lower limb blood flow in chronic heart failure.

Authors:  D C Lindsay; D R Holdright; D Clarke; I S Anand; P A Poole-Wilson; P Collins
Journal:  Heart       Date:  1996-05       Impact factor: 5.994

Review 6.  The role of exercise training in chronic heart failure.

Authors:  R P Wielenga; A J Coats; W L Mosterd; I A Huisveld
Journal:  Heart       Date:  1997-11       Impact factor: 5.994

Review 7.  Novel drugs and current therapeutic approaches in the treatment of heart failure.

Authors:  V V Bonarjee; K Dickstein
Journal:  Drugs       Date:  1996-03       Impact factor: 9.546

Review 8.  Heart failure: What causes the symptoms of heart failure?

Authors:  A J Coats
Journal:  Heart       Date:  2001-11       Impact factor: 5.994

Review 9.  Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training.

Authors:  Brian D Duscha; P Christian Schulze; Jennifer L Robbins; Daniel E Forman
Journal:  Heart Fail Rev       Date:  2008-02       Impact factor: 4.214

10.  Intermittent infusion of dobutamine in the therapy of severe congestive heart failure--long-term effects and lack of tolerance.

Authors:  H H Erlemeier; W Kupper; W Bleifeld
Journal:  Cardiovasc Drugs Ther       Date:  1992-08       Impact factor: 3.727

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.